白细胞介素-17抑制剂与念珠菌病相关的风险:影响和管理

IF 4.6 2区 生物学 Q1 MYCOLOGY Mycology Pub Date : 2023-10-20 DOI:10.1080/21501203.2023.2265664
Hazrat Bilal, Muhammad Nadeem Khan, Sabir Khan, Wenjie Fang, Wenqiang Chang, Bin Yin, Ning-Jing Song, Zhongrong Liu, Dongxing Zhang, Fen Yao, Xun Wang, Qian Wang, Lin Cai, Bing Hou, Jiayue Wang, Chunyan Mao, Lingxi Liu, Yuebin Zeng
{"title":"白细胞介素-17抑制剂与念珠菌病相关的风险:影响和管理","authors":"Hazrat Bilal, Muhammad Nadeem Khan, Sabir Khan, Wenjie Fang, Wenqiang Chang, Bin Yin, Ning-Jing Song, Zhongrong Liu, Dongxing Zhang, Fen Yao, Xun Wang, Qian Wang, Lin Cai, Bing Hou, Jiayue Wang, Chunyan Mao, Lingxi Liu, Yuebin Zeng","doi":"10.1080/21501203.2023.2265664","DOIUrl":null,"url":null,"abstract":"The application of interleukin-17 (IL-17) inhibitors, including secukinumab, ixekizumab, brodalumab, and bimekizumab, are associated with elevated risk of candidiasis. These medications interfere with the IL-17 pathway, which is essential for maintaining mucosal barriers and coordinating the immune response against Candida species. The observational data and clinical trials demonstrate the increased incidence of candidiasis in individuals treated with IL-17 inhibitors. Brodalumab and bimekizumab pose a greater risk than secukinumab in eliciting candidiasis, whereas the data regarding ixekizumab are equivocal. Higher doses and prolonged treatment duration of IL-17 inhibitors increase the risk of candidiasis by compromising the immune response against Candida species. Prior to prescribing IL-17 inhibitors, healthcare professionals should comprehensively evaluate patients’ medical histories and assess their risk factors. Patients should be educated on the signs and symptoms of candidiasis to facilitate early detection and intervention. Future research should focus on identifying the risk factors associated with candidiasis in patients receiving IL-17 inhibitors. Prospective studies and long-term surveillance are required to explore the impact of specific inhibitors on the incidence and severity of candidiasis and to evaluate the effectiveness of combination therapies, such as concurrent use of IL-17 inhibitors and prophylactic antifungal agents.","PeriodicalId":18833,"journal":{"name":"Mycology","volume":null,"pages":null},"PeriodicalIF":4.6000,"publicationDate":"2023-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Risk of candidiasis associated with interleukin-17 inhibitors: implications and management\",\"authors\":\"Hazrat Bilal, Muhammad Nadeem Khan, Sabir Khan, Wenjie Fang, Wenqiang Chang, Bin Yin, Ning-Jing Song, Zhongrong Liu, Dongxing Zhang, Fen Yao, Xun Wang, Qian Wang, Lin Cai, Bing Hou, Jiayue Wang, Chunyan Mao, Lingxi Liu, Yuebin Zeng\",\"doi\":\"10.1080/21501203.2023.2265664\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The application of interleukin-17 (IL-17) inhibitors, including secukinumab, ixekizumab, brodalumab, and bimekizumab, are associated with elevated risk of candidiasis. These medications interfere with the IL-17 pathway, which is essential for maintaining mucosal barriers and coordinating the immune response against Candida species. The observational data and clinical trials demonstrate the increased incidence of candidiasis in individuals treated with IL-17 inhibitors. Brodalumab and bimekizumab pose a greater risk than secukinumab in eliciting candidiasis, whereas the data regarding ixekizumab are equivocal. Higher doses and prolonged treatment duration of IL-17 inhibitors increase the risk of candidiasis by compromising the immune response against Candida species. Prior to prescribing IL-17 inhibitors, healthcare professionals should comprehensively evaluate patients’ medical histories and assess their risk factors. Patients should be educated on the signs and symptoms of candidiasis to facilitate early detection and intervention. Future research should focus on identifying the risk factors associated with candidiasis in patients receiving IL-17 inhibitors. Prospective studies and long-term surveillance are required to explore the impact of specific inhibitors on the incidence and severity of candidiasis and to evaluate the effectiveness of combination therapies, such as concurrent use of IL-17 inhibitors and prophylactic antifungal agents.\",\"PeriodicalId\":18833,\"journal\":{\"name\":\"Mycology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":4.6000,\"publicationDate\":\"2023-10-20\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Mycology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1080/21501203.2023.2265664\",\"RegionNum\":2,\"RegionCategory\":\"生物学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"MYCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Mycology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/21501203.2023.2265664","RegionNum":2,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MYCOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

白介素-17 (IL-17)抑制剂的应用,包括secukinumab、ixekizumab、brodalumab和bimekizumab,与念珠菌病的风险升高相关。这些药物干扰IL-17通路,这对于维持粘膜屏障和协调针对念珠菌的免疫反应至关重要。观察性数据和临床试验表明,使用IL-17抑制剂治疗的个体中念珠菌病的发病率增加。Brodalumab和bimekizumab在引发念珠菌病方面比secukinumab具有更大的风险,而关于ixekizumab的数据则模棱两可。较高剂量和较长的IL-17抑制剂治疗时间会损害针对念珠菌的免疫反应,从而增加念珠菌病的风险。在处方IL-17抑制剂之前,医疗保健专业人员应全面评估患者的病史并评估其风险因素。应教育患者有关念珠菌病的体征和症状,以促进早期发现和干预。未来的研究应侧重于确定接受IL-17抑制剂的患者中与念珠菌病相关的危险因素。需要前瞻性研究和长期监测来探索特异性抑制剂对念珠菌病发病率和严重程度的影响,并评估联合治疗的有效性,例如同时使用IL-17抑制剂和预防性抗真菌药物。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Risk of candidiasis associated with interleukin-17 inhibitors: implications and management
The application of interleukin-17 (IL-17) inhibitors, including secukinumab, ixekizumab, brodalumab, and bimekizumab, are associated with elevated risk of candidiasis. These medications interfere with the IL-17 pathway, which is essential for maintaining mucosal barriers and coordinating the immune response against Candida species. The observational data and clinical trials demonstrate the increased incidence of candidiasis in individuals treated with IL-17 inhibitors. Brodalumab and bimekizumab pose a greater risk than secukinumab in eliciting candidiasis, whereas the data regarding ixekizumab are equivocal. Higher doses and prolonged treatment duration of IL-17 inhibitors increase the risk of candidiasis by compromising the immune response against Candida species. Prior to prescribing IL-17 inhibitors, healthcare professionals should comprehensively evaluate patients’ medical histories and assess their risk factors. Patients should be educated on the signs and symptoms of candidiasis to facilitate early detection and intervention. Future research should focus on identifying the risk factors associated with candidiasis in patients receiving IL-17 inhibitors. Prospective studies and long-term surveillance are required to explore the impact of specific inhibitors on the incidence and severity of candidiasis and to evaluate the effectiveness of combination therapies, such as concurrent use of IL-17 inhibitors and prophylactic antifungal agents.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Mycology
Mycology Medicine-Infectious Diseases
CiteScore
9.10
自引率
0.00%
发文量
18
审稿时长
13 weeks
期刊最新文献
The Vps21 signalling pathway regulates white-opaque switching and mating in Candida albicans Editorial comment – fungi-mediated bioremediation and bioconversion Insights into the evolution and mechanisms of response to heat stress by whole genome sequencing and comparative proteomics analysis of the domesticated edible mushroom Lepista sordida New bioactive secondary metabolites from fungi: 2023 An alignment- and reference-free strategy using k -mer present pattern for population genomic analyses
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1